Biomex GmbH products

CTS serology panels are used to meet the requirements of the new European Regulation 2017/746 on in-vitro-diagnostics. This regulation replaces the previous Directive 98/79/EC and will need to be implemented by May 26, 2022. 

In order to validate diagnostic specificity for assays that need not be tested according to the comprehensive specifications of the CTS, we also offer a variety of different panels: Cross-reaction panels (RF+, HAMA,...), Inhibition panels (endogenous factors), Negative samples, Hospitalized patient panels, Cross-contamination panels, Serum/Plasma equivalence panels, Blood bank marker panels,